SEARCH

SEARCH BY CITATION

References

  • 1
    McHutchinson JG. Understanding hepatitis C. Am J Manag Care 2004; 10: S21S29.
  • 2
    Choo QL, Kuo G, Weiner AJ et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359362.
  • 3
    Kuo G, Choo QL, Alter HJ et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362364.
  • 4
    Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47: 139.
  • 5
    Alter MJ, Kruszon-Moran D, Mainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556562.
  • 6
    Fried M, Hoofnagle J. Therapy of hepatitis C. Semin Liver Dis 1995; 15(1): 8291.
  • 7
    Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352(9138): 14261432.
  • 8
    McHutchinson JG, Gordon SC, Schiff ER et al. and the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 14851492.
  • 9
    Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226231.
  • 10
    Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343(23): 16661672.
  • 11
    Nieforth KA, Nadeau R, Patel ICH, Mould D. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 1996; 59: 636646.
  • 12
    Reddy KR, Wright TL, Pockros PJ et al.. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33(2): 433438.
  • 13
    Heathcote EJ, Shiffman ML, Cooksley WG et al., De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343(23): 16731680.
  • 14
    Fried MW, Shiffman ML, Reddy KR et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975982.
  • 15
    National Institutes of Diabetes and Digestive and Kidney Disorders, National Institutes of health. Chronic Hepatitis C: Current Disease Management. NIH Publication No. 02-4230, February 2003. http://digestive.niddk.nih.gov/ddiseases/pubs/chronichepc/chronichepc.pdf (accessed 14 November 2003).
  • 16
    National Institutes of Health. Consensus Development Conference Statement: Management of hepatitis C: 2003–June 10–12, 2002. Hepatology 2002; 36: S1S20.
  • 17
    Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39(4): 11471171.
  • 18
    Ferenci P. Current treatment for chronic hepatitis C. Curr Treat Options Gastroenterol 2004; 7(6): 491499.
  • 19
    Hadziyannis SJ, Sette H Jr, Morgan TR et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140(5): 346355.
  • 20
    Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22(6): 696699.
  • 21
    Bacon BR. Managing hepatitis C. Am J Manag Care 2004; 10(2 Suppl): S30S40.
  • 22
    Lee SS, Heathcote EJ, Reddy KR et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40 KD). J Hepatol 2002; 37(4): 500506.
  • 23
    Berg T, Von Wagner M, Hinrichsen H et al. Definition of a pre-treatment viral load cut-off for an optimized prediction of treatment outcome in patients with genotype 1 infection receiving either 48 or 72 weeks of peginterferon alfa-2a plus ribavirin. Hepatology 2006; 44(4, Suppl. 1): A350.
  • 24
    Zehnter E., Mauss S., John C. et al. Better prediction of SVR in patients with HCV genotype 1 (GT1) with Peginterferon alfa-2a (Pegasys) plus ribavirin: improving differentiation between low (LVL) and high baseline viral load (HVL). Hepatology 2006; 44(4, Suppl. 1): 0A368.
  • 25
    Fried M. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237S244.
  • 26
    Shiffman ML, Di Bisceglie AM, Lindsay KL et al. Hepatitis C antiviral long-term treatment against cirrhosis trial group. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126(4): 10151023.